Reassessing the Role of Somatostatin Analogs in the Treatment of NETs

Slides:

Advertisements

Similar presentations

What’s new in NETs? Lucy Wall Consultant Medical Oncologist Ann Edgar Patient Forum 10 th May 2013.

Advertisements

Phase Difference = Phase Difference = 0.05.

Luciano M. Vargas Jr. MD Jean Grem MD Lucienne Case RN Haley Armstrong Review & Update Neuroendocrine Tumor Management.

Case Presentation: Neuroendocrine Tumor in the Midgut

Clinical Trials The Way We Make Progress Against Disease.

Carla Chieffo, David Cook, Qinfang Xiang, and Lawrence A. Frohman Efficacy and Safety of an Octreotide Implant in the Treatment of Patients With Acromegaly.

Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.

NET MASTERCLASS GI-NEUROENDOCRINE TUMORS: THERAPEUTIC APPROACHES: SYMPTOMATIC MANAGEMENT IOANNIS PILPILIDIS, MD, FEBGH GASTROENTEROLOGY – ONCOLOGY.

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Short-, Intermediate-, Long-Acting Insulins

Novel Targets and Treatment Approaches for GEP-NETs

Primary Care Challenges in Depression - To Treat or Refer?

New ESMO Guidance on Tumor Sidedness in mCRC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

Improving Survival in Glioblastoma Multiforme

Non-GIST Soft Tissue Sarcoma: Biology and Basics of Targeted Therapy

What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

Updates in Hodgkin Lymphoma

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Update: Neuroendocrine Tumors

REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Study Design

COORDINATED CARE IN CUSHING DISEASE

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Program Goals. ESSENTIAL CONCEPTS IN THE USE OF SOMATOSTATIN ANALOGUES IN PATIENTS WITH NEUROENDOCRINE TUMORS.

Program Goals. The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC.

PARP Inhibitors and Cancer: What Do You Need to Know?

The Mood Disorder Spectrum

CDK4/6 Inhibitors in Breast Cancer:

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic.

Activity Goals. Activity Goals Case Presentation.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

More Than Meets the Eye.

Case Studies in Unresectable Hepatocellular Carcinoma

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

ADVANCED PARKINSON'S DISEASE:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Breast Cancer Statistics

Personalizing Management in the Care of Patients With Advanced Sarcoma

Program Goals Overview Is NEDA a Reasonable Target?

Maintenance Therapy in Advanced Ovarian Cancer

After the Baby Comes.

Locally Advanced Lung Cancer

Treatment of Locally Advanced Pancreatic Cancer

Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Selecting and Applying Chemotherapy

Are We Making Progress in the Management of Huntington Disease?

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

PREGNANCY AND ITS HORMONAL CONTROL.

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

First-Line FCR: Effect of del(17p) on PFS and OS

Improving Outcomes in Patients With SSc-ILD

A Multidisciplinary Perspective on the Management of Hypoparathyroidism.

Watchful waiting: Is it a choice? PRO

When Good Isn't Good Enough

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Disease Burden of VTE Phases of VTE Treatment.

Program Goals Overview Is NEDA a Reasonable Target?

Taking a Closer Look at Recurrent/Metastatic SCCHN

Evaluating Success of Current Treatments for HCM

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease.

Understanding the Role of Disability in MS Management

Foundations of Asthma.

Presentation transcript:

Reassessing the Role of Somatostatin Analogs in the Treatment of NETs

Activity Goals

Categories of NETs

Carcinoid Tumors

Symptoms From Hormone Production

Somatostatin Analog

The PROMID Study Design

PROMID Study Results

CLARINET Study

CLARINET Study: Results

Differences Between Studies

Phase 3: Pasireotide vs Octreotide

Phase 3 Study: Results

Curve to Show Difference in Disease Control?

ELECT Study

ELECT Study

Temozolomide-based Regimens

CAPTEM

PFS and OS With CAPTEM

Conclusions

Streptozocin-based Regimens

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)